Adimmune's 3rd Filling Line Passes GMP Certification, Prioritizes Influenza Vaccine Production
Adimmune Corporation announced that its newly expanded third automated sterile filling line has passed inspection by Taiwan's Food and Drug Administration (TFDA) and is certified for Good Manufacturing Practice (GMP). The new line will first be used for this year's influenza vaccine production due to a strain change. It is expected to boost annual capacity by 4 million doses and will also serve other clients with GMP production needs, increasing existing capacity efficiency and production flexibility.
📋 Article Processing Timeline
- 📰 Published: April 14, 2026 at 18:14
- 🔍 Collected: April 14, 2026 at 18:31 (17 min after Published)
- 🤖 AI Analyzed: April 14, 2026 at 20:41 (2h 9m after Collected)
Taipei, April 14 (CNA) - Adimmune Biotech has announced that its newly completed 3rd automated sterile filling line has passed an inspection by the Taiwan Food and Drug Administration (TFDA) and is certified to be in compliance with Good Manufacturing Practice (GMP) for pharmaceuticals. The new production line will be prioritized for the production of this year's influenza vaccine following a change in virus strains. In the future, it will also serve more clients in need of GMP production, enhancing current capacity efficiency and increasing production flexibility.
Adimmune stated in a press release today that due to the first and second production lines already operating at full capacity, a third automated sterile filling and packaging line was constructed. The company applied for GMP certification from the TFDA in December of last year, and after an on-site inspection, received GMP approval in early April this year.
Hung Yueh-Peng, Vice President of Business at Adimmune, pointed out that the third line features the use of single-use filling kits, which significantly lowers the barrier for GMP mass production. It offers customized services with an optimal production scale for single-batch, small-volume clinical trial batches or high-value biologic drug production. Clients have already approached the company for production collaborations. With the third line online, the estimated annual capacity can reach 4 million doses.
Adimmune stated that in addition to meeting the demand for high-value, small-batch, and diversified production, the third line also greatly contributes to improving the efficiency of Adimmune's existing lines and increasing the flexibility of production scheduling. Hung Yueh-Peng noted that previously, Adimmune's enterovirus and tetanus vaccines had to occupy the first and second production lines, which could lead to a crowding-out effect, especially during the peak season for seasonal influenza vaccine production. With the third line now operational, it can handle small-batch production tasks, freeing up excess capacity to serve commercial mass-production clients and improving production efficiency and capacity value.
The first task for the third production line is the small-batch production for this year's government-funded influenza vaccine due to a change in the virus strain, with the primary goal of supplying the flu vaccines needed by the public for autumn and winter epidemic prevention on schedule.
Adimmune pointed out that since the third line can satisfy clients' needs from front-end clinical trials to back-end commercial mass production, there is demand not only from international clients but also from several domestic pharmaceutical companies seeking production collaborations. Therefore, the third line will also apply for US and EU GMP certification to meet the customized production needs of international clients. The three existing lines provide clients with a one-stop service from clinical trials to commercial mass production, giving the company an advantage in securing international production collaborations and serving as a backbone for Adimmune's expansion into the international market. (Editor: Yang Kai-Hsiang) 1150414
Adimmune stated in a press release today that due to the first and second production lines already operating at full capacity, a third automated sterile filling and packaging line was constructed. The company applied for GMP certification from the TFDA in December of last year, and after an on-site inspection, received GMP approval in early April this year.
Hung Yueh-Peng, Vice President of Business at Adimmune, pointed out that the third line features the use of single-use filling kits, which significantly lowers the barrier for GMP mass production. It offers customized services with an optimal production scale for single-batch, small-volume clinical trial batches or high-value biologic drug production. Clients have already approached the company for production collaborations. With the third line online, the estimated annual capacity can reach 4 million doses.
Adimmune stated that in addition to meeting the demand for high-value, small-batch, and diversified production, the third line also greatly contributes to improving the efficiency of Adimmune's existing lines and increasing the flexibility of production scheduling. Hung Yueh-Peng noted that previously, Adimmune's enterovirus and tetanus vaccines had to occupy the first and second production lines, which could lead to a crowding-out effect, especially during the peak season for seasonal influenza vaccine production. With the third line now operational, it can handle small-batch production tasks, freeing up excess capacity to serve commercial mass-production clients and improving production efficiency and capacity value.
The first task for the third production line is the small-batch production for this year's government-funded influenza vaccine due to a change in the virus strain, with the primary goal of supplying the flu vaccines needed by the public for autumn and winter epidemic prevention on schedule.
Adimmune pointed out that since the third line can satisfy clients' needs from front-end clinical trials to back-end commercial mass production, there is demand not only from international clients but also from several domestic pharmaceutical companies seeking production collaborations. Therefore, the third line will also apply for US and EU GMP certification to meet the customized production needs of international clients. The three existing lines provide clients with a one-stop service from clinical trials to commercial mass production, giving the company an advantage in securing international production collaborations and serving as a backbone for Adimmune's expansion into the international market. (Editor: Yang Kai-Hsiang) 1150414
FAQ
What are the main features of Adimmune's new 3rd production line?
The 3rd filling line uses single-use filling kits, making it suitable for small-batch production and high-value biologics. It has an estimated annual capacity of 4 million doses and increases production flexibility.
What is the first task for this new line?
Its first task is the small-batch production for this year's government-funded influenza vaccine, following a change in the required virus strain, aiming to supply it in time for autumn and winter epidemic prevention needs.